Combining Omalizumab with Another Biotherapy

Acta Derm Venereol. 2019 Apr 1;99(4):448-449. doi: 10.2340/00015555-3140.
No abstract available

Publication types

  • Observational Study

MeSH terms

  • Adult
  • Anti-Allergic Agents / adverse effects
  • Anti-Allergic Agents / therapeutic use*
  • Biological Products / adverse effects
  • Biological Products / therapeutic use*
  • Chronic Disease
  • Colitis, Ulcerative / diagnosis
  • Colitis, Ulcerative / drug therapy*
  • Colitis, Ulcerative / immunology
  • Crohn Disease / diagnosis
  • Crohn Disease / drug therapy*
  • Crohn Disease / immunology
  • Female
  • Humans
  • Immunoglobulin E / immunology
  • Male
  • Middle Aged
  • Omalizumab / adverse effects
  • Omalizumab / therapeutic use*
  • Psoriasis / diagnosis
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • Retrospective Studies
  • Spondylitis, Ankylosing / diagnosis
  • Spondylitis, Ankylosing / drug therapy*
  • Spondylitis, Ankylosing / immunology
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology
  • Urticaria / diagnosis
  • Urticaria / drug therapy*
  • Urticaria / immunology
  • Young Adult

Substances

  • Anti-Allergic Agents
  • Biological Products
  • Tumor Necrosis Factor-alpha
  • Omalizumab
  • Immunoglobulin E